DLL3 and small cell lung carcinoma: Conversely, expression of DLL3, the target of multiple agents currently under clinical investigation in SCLC (antibody drug conjugates, T cell engagers, CAR–T cells) (35, 36), was restricted to NEPC tumors (Figure 1I) and showed strong concordance with NEPC TFs (CCC=0.9, 95% CI 0.87 – 0.93) (Supplementary Figure 1F).